Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ionis Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Ionis Pharmaceuticals, Inc.’s stock price such as:

• Ionis Pharmaceuticals, Inc.’s current stock price and volume
• Why Ionis Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for IONS from analysts
• IONS’s stock price momentum as measured by its relative strength

About Ionis Pharmaceuticals, Inc. (IONS)

Before we jump into Ionis Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Want to learn more about Ionis Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of December 02, 2025, 4:00 PM, CST, Ionis Pharmaceuticals, Inc.’s stock price was $81.310.

Ionis Pharmaceuticals, Inc. is down 0.83% from its previous closing price of $81.990.

During the last market session, Ionis Pharmaceuticals, Inc.’s stock traded between $80.000 and $82.690. Currently, there are approximately 159.77 million shares outstanding for Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ionis Pharmaceuticals, Inc. Stock Price History

Ionis Pharmaceuticals, Inc.’s (IONS) price is currently down 1.72% so far this month.

During the month of December, Ionis Pharmaceuticals, Inc.’s stock price has reached a high of $82.690 and a low of $80.000.

Over the last year, Ionis Pharmaceuticals, Inc. has hit prices as high as $82.950 and as low as $23.950. Year to date, Ionis Pharmaceuticals, Inc.’s stock is up 132.58%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ionis Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there was 1 analyst who downgraded Ionis Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ionis Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ionis Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ionis Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ionis Pharmaceuticals, Inc. (IONS) by visiting AAII Stock Evaluator.

Relative Price Strength of Ionis Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Ionis Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 24.71%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Ionis Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ionis Pharmaceuticals, Inc. Stock Price: Bottom Line

As of December 2, 2025, Ionis Pharmaceuticals, Inc.’s stock price is $81.310, which is down 0.83% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ionis Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.